Nothing Special   »   [go: up one dir, main page]

UA83798C2 - Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами - Google Patents

Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами

Info

Publication number
UA83798C2
UA83798C2 UA20040907817A UA20040907817A UA83798C2 UA 83798 C2 UA83798 C2 UA 83798C2 UA 20040907817 A UA20040907817 A UA 20040907817A UA 20040907817 A UA20040907817 A UA 20040907817A UA 83798 C2 UA83798 C2 UA 83798C2
Authority
UA
Ukraine
Prior art keywords
treatment
epothilones
proliferative processes
diseases associated
brain diseases
Prior art date
Application number
UA20040907817A
Other languages
English (en)
Ukrainian (uk)
Inventor
Роземарие Лихтнер
Андреа Ротгери
Йенс Хоффманн
Бернд Бухманн
Вольфганг Шведе
Original Assignee
Шеринг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27675676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA83798(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг Аг filed Critical Шеринг Аг
Publication of UA83798C2 publication Critical patent/UA83798C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение касается применения эпотилона, который имеет коэффициент среднего распределения между плазмой и мозгом 0,3-1,5 в анализе на мышах с помощью внутривенной болюсной инъекции, при получении лекарственного средства для терапии болезни мозга, ассоциированной с пролиферативными процессами.
UA20040907817A 2002-03-01 2003-02-28 Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами UA83798C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36106202P 2002-03-01 2002-03-01
EP02004745A EP1340498A1 (en) 2002-03-01 2002-03-01 Use of epothilones in the treatment of brain diseases associated with proliferative processes
PCT/EP2003/002085 WO2003074053A1 (en) 2002-03-01 2003-02-28 Use of epothilones in the treatment of brain diseases associated with proliferative processes

Publications (1)

Publication Number Publication Date
UA83798C2 true UA83798C2 (ru) 2008-08-26

Family

ID=27675676

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040907817A UA83798C2 (ru) 2002-03-01 2003-02-28 Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами

Country Status (23)

Country Link
US (1) US20040019088A1 (ru)
EP (2) EP1340498A1 (ru)
JP (1) JP2005525360A (ru)
KR (1) KR20040095244A (ru)
CN (1) CN100473381C (ru)
AR (1) AR038712A1 (ru)
AU (1) AU2003215618B2 (ru)
BR (1) BR0308154A (ru)
CA (1) CA2477403A1 (ru)
CR (1) CR7444A (ru)
EC (1) ECSP045340A (ru)
HK (1) HK1079998A1 (ru)
HR (1) HRP20040892A2 (ru)
IL (1) IL163752A0 (ru)
MX (1) MXPA04008450A (ru)
NO (1) NO20044175L (ru)
NZ (1) NZ546617A (ru)
PL (1) PL370768A1 (ru)
RU (1) RU2351330C2 (ru)
UA (1) UA83798C2 (ru)
WO (1) WO2003074053A1 (ru)
YU (1) YU76404A (ru)
ZA (1) ZA200407905B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2299608A1 (en) * 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
BR0008206A (pt) * 1999-02-11 2002-02-19 Schering Ag Derivados de epotilon, processos para a sua preparação e sua aplicação farmacêutica
US7125893B1 (en) * 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
CN102532120A (zh) 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 埃坡霉素(epothilone)，合成埃坡霉素的中间体，其类似物及其用途
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE10331004A1 (de) * 2003-07-03 2005-02-24 Schering Ag Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten
EP1559447A1 (en) * 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1700596A1 (en) * 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
DE102007016046A1 (de) * 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
TWI472329B (zh) 2008-04-24 2015-02-11 必治妥美雅史谷比公司 埃坡徽素ｄ於治療包括阿茲海默症之ｔａｕ相關疾病的用途
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3226545B2 (ja) * 1995-06-09 2001-11-05 ノバルティス・アクチエンゲゼルシャフト ラパマイシン誘導体
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
BR9807418A (pt) * 1997-02-18 2002-01-22 Canji Inc Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CA2299608A1 (en) * 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
JP4434484B2 (ja) * 1997-12-04 2010-03-17 ブリストル−マイヤーズ スクイブ カンパニー オキシラニルエポチロン化合物のオレフィン性エポチロン化合物への還元法
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
AU4775299A (en) * 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
ES2291194T3 (es) * 1999-02-18 2008-03-01 Bayer Schering Pharma Aktiengesellschaft Derivados de 16-halogeno-epotilones, procedimiento acerca de su preparacion y su utilizacion farmaceutica.
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
EP2289549A3 (en) * 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
GB0013643D0 (en) * 2000-05-31 2000-07-26 Unilever Plc Targeted moieties for use in bleach catalysts
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives

Also Published As

Publication number Publication date
ECSP045340A (es) 2004-11-26
US20040019088A1 (en) 2004-01-29
AR038712A1 (es) 2005-01-26
NO20044175L (no) 2004-12-01
EP1340498A1 (en) 2003-09-03
YU76404A (sh) 2006-08-17
BR0308154A (pt) 2005-01-04
IL163752A0 (en) 2005-12-18
EP1480643A1 (en) 2004-12-01
RU2351330C2 (ru) 2009-04-10
AU2003215618A1 (en) 2003-09-16
AU2003215618B2 (en) 2009-06-04
CA2477403A1 (en) 2003-09-12
WO2003074053A1 (en) 2003-09-12
PL370768A1 (en) 2005-05-30
ZA200407905B (en) 2006-04-26
HRP20040892A2 (en) 2004-12-31
CR7444A (es) 2005-10-05
NZ546617A (en) 2007-12-21
MXPA04008450A (es) 2005-07-13
CN100473381C (zh) 2009-04-01
HK1079998A1 (zh) 2006-04-21
CN1649587A (zh) 2005-08-03
RU2004129325A (ru) 2005-07-10
KR20040095244A (ko) 2004-11-12
JP2005525360A (ja) 2005-08-25

Similar Documents

Publication Publication Date Title
UA83798C2 (ru) Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами
NZ595313A (en) The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
LUC00011I1 (ru)
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
SG163583A1 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2005084377A3 (en) Combination therapy with glatiramer acetate and riluzole
WO2004103267A3 (en) Methods to administer epothilone d
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
MXPA05013958A (es) Tratamiento de cancer con epotilona.